Journal of Vascular Surgery
Volume 47, Issue 1 , Pages 55-62 , January 2008

The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability

Presented at the 2007 Vascular Annual Meeting, Baltimore, Md, Jun 6-10, 2007.

  • Nikolaos P.E. Kadoglou, MD, MSc

      Affiliations

    • Department of Vascular Surgery, Medical School, University of Athens, Athens, Greece
    • First Department of Internal Medicine, “Hippokratio” General Hospital, Thessaloniki, Greece
    • Corresponding Author InformationCorrespondence: Nikolaos P. E. Kadoglou, MD, MSc, 124 Vosporou str, 54454 Thessaloniki Greece.
    • ,
  • Thomas Gerasimidis, MD

      Affiliations

    • Fifth Surgical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece
    • ,
  • Spyretta Golemati, PhD

      Affiliations

    • Department of Vascular Surgery, Medical School, University of Athens, Athens, Greece
    • ,
  • Alkistis Kapelouzou, BSc

      Affiliations

    • Foundation of Biomedical Research, Center for Experimental Surgery, Academy of Athens, Athens, Greece.
    • ,
  • Panayiotis E. Karayannacos, MD, FACS

      Affiliations

    • Foundation of Biomedical Research, Center for Experimental Surgery, Academy of Athens, Athens, Greece.
    • ,
  • Christos D. Liapis, MD, FACS, FRCS

      Affiliations

    • Department of Vascular Surgery, Medical School, University of Athens, Athens, Greece

Received 4 June 2007 ,Accepted 20 September 2007.

References 

  1. Kakkos SK, Stevens JM, Nicolaides AN, Kyriacou E, Pattichis CS, Geroulakos G, et al. Texture analysis of ultrasonic images of symptomatic carotid plaques can identify those plaques associated with ipsilateral embolic brain infarction. Eur J Vasc Endovasc Surg. 2007;33:422–429
  2. Nighoghossian N, Derex L, Douek P. The vulnerable carotid artery plaque: current imaging methods and new perspectives. Stroke. 2005;36:2764–2772
  3. Liapis CD, Kakisis JD, Kostakis AG. Carotid stenosis: factors affecting symptomatology. Stroke. 2001;32:2782–2786
  4. Grogan JK, Shaalan WE, Cheng H, Gewertz B, Desai T, Schwarze G, et al. B-mode ultrasonographic characterization of carotid atherosclerotic plaques in symptomatic and asymptomatic patients. J Vasc Surg. 2005;42:435–441
  5. Johnson RC, Leopold JA, Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res. 2006;99:1044–1059
  6. Shaalan WE, Cheng H, Gewertz B, McKinsey JF, Schwartz LB, Katz D, et al. Degree of carotid plaque calcification in relation to symptomatic outcome and plaque inflammation. J Vasc Surg. 2004;40:262–269
  7. Raggi P, Cooil B, Shaw LJ, Aboulhson J, Takasu J, Budoff M, et al. Progression of coronary calcium on serial electron beam tomographic scanning is greater in patients with future myocardial infarction. Am J Cardiol. 2003;92:827–829
  8. Ehara S, Kobayashi Y, Yoshiyama M, Shimada K, Shimada Y, Fukuda D, et al. Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study. Circulation. 2004;110:3424–3429
  9. Denhardt DT, Noda M, O’Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001;107:1055–1061
  10. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol. 2004;24:1161–1170
  11. O’Brien ER, Garvin MR, Stewart DK, Hinohara T, Simpson JB, Schwartz SM, et al. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb. 1994;14:1648–1656
  12. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol. 2002;22:549–553
  13. Hofbauer LC, Shui C, Riggs BL, Dunstan CR, Spelsberg TC, O’Brien T, et al. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun. 2001;280:334–339
  14. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002;106:1192–1194
  15. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004;109:2175–2180
  16. Grant EG, Benson CB, Moneta GL, Alexandrov AV, Baker JD, Bluth EI, et al. Carotid artery stenosis: gray-scale and Doppler US diagnosis–Society of Radiologists in Ultrasound Consensus Conference. Radiology. 2003;229:340–346
  17. Stoitsis J, Golemati S, Nikita KS. A modular software system to assist interpretation of medical images – application to vascular ultrasound images. IEEE Trans Instrum Meas. 2006;55:1944–1952
  18. Elatrozy T, Nicolaides A, Tegos T, Zarka A, Griffin M, Sabetai M. The effect of B-mode ultrasonic image standardization of the echodensity of symptomatic and asymptomatic carotid bifurcation plaque. Int Angiol. 1998;7:179-6
  19. Ohmori R, Momiyama Y, Taniguchi H, Takahashi R, Kusuhara M, Nakamura H, et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis. 2003;170:333–337
  20. Kurata M, Okura T, Watanabe S, Fukuoka T, Higaki J. Osteopontin and carotid atherosclerosis in patients with essential hypertension. Clin Sci (Lond). 2006;111:319–324
  21. Chiba S, Okamoto H, Kon S, Kimura C, Murakami M, Inobe M, et al. Development of atherosclerosis in osteopontin transgenic mice. Heart Vessels. 2002;16:111–117
  22. Matsui Y, Rittling SR, Okamoto H, Inobe M, Jia N, Shimizu T, et al Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:1029–1034
  23. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 2000;287:860–864
  24. Li JJ, Han M, Wen JK, Li AY. Osteopontin stimulates vascular smooth muscle cell migration by inducing FAK phosphorylation and ILK dephosphorylation. Biochem Biophys Res Commun. 2007;356:13–19
  25. Golledge J, McCann M, Mangan S, Lam A, Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke. 2004;35:1636–1641
  26. Isoda K, Nishikawa K, Kamezawa Y, Yoshida M, Kusuhara M, Moroi M, et al. Osteopontin plays an important role in the development of medial thickening and neointimal formation. Circ Res. 2002;91:77–82
  27. Kadoglou NP, Daskalopoulou SS, Perrea D, Liapis CD. Matrix metalloproteinases and diabetic vascular complications. Angiology. 2005;56:173–189
  28. Tureyen K, Vemuganti R, Salamat MS, Dempsey RJ. Increased angiogenesis and angiogenic gene expression in carotid artery plaques from symptomatic stroke patients. Neurosurgery. 2006;58:971–977
  29. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001;86:631–637
  30. Vik A, Mathiesen EB, Noto AT, Sveinbjornsson B, Brox J, Hansen JB. Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans. Atherosclerosis. 2007;191:128–134
  31. Kim SM, Lee J, Ryu OH, Lee KW, Kim HY, Seo JA, et al. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clin Endocrinol (Oxf). 2005;63:594–598
  32. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol. 2006;47:1850–1857
  33. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260–1268
  34. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med. 2000;192:463–474
  35. Menke A, Muntner P, Wildman RP, Reynolds K, He J. Measures of adiposity and cardiovascular disease risk factors. Obesity (Silver Spring). 2007;15:785–795
  36. Guzik TJ, Mangalat D, Korbut R. Adipocytokines - novel link between inflammation and vascular function?. J Physiol Pharmacol. 2006;57:505–528
  37. De Michele M, Panico S, Iannuzzi A, Celentano E, Ciardullo AV, Galasso R, et al. Association of obesity and central fat distribution with carotid artery wall thickening in middle-aged women. Stroke. 2002;33:2923–2928
  38. Bidder M, Shao JS, Charlton-Kachigian N, Loewy AP, Semenkovich CF, Towler DA. Osteopontin transcription in aortic vascular smooth muscle cells is controlled by glucose-regulated upstream stimulatory factor and activator protein-1 activities. J Biol Chem. 2002;277:44485–44496
  39. Takemoto M, Yokote K, Nishimura M, Shigematsu T, Hasegawa T, Kon S, et al. Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis. Arterioscler Thromb Vasc Biol. 2000;20:624–628
  40. Ravipati G, Aronow WS, Ahn C, Channamsetty V, Sekhri V. Incidence of new stroke or new myocardial infarction or death in patients with severe carotid arterial disease treated with and without statins. Am J Cardiol. 2006;98:1170–1171

 Competition of interest: none.

PII: S0741-5214(07)01535-2

doi: 10.1016/j.jvs.2007.09.058

Journal of Vascular Surgery
Volume 47, Issue 1 , Pages 55-62 , January 2008

Article Tools

* Image Usage & Resolution